## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence presented in the abstract; no access to full methods, figures, or supplementary data
- **Shared manuscript claim summary** The authors report that heterozygous mutations in the DM domain of DMRT1, specifically p.Pro74Leu, reduce DNA binding affinity and are associated with idiopathic non-obstructive azoospermia (NOA). They support this with exome sequencing, an EMSA assay, molecular dynamic simulations, and burden testing against population controls. They also report rare deleterious DMRT1 variants in primary ovarian insufficiency (POI) cases, suggesting a possible link.
- **Visible evidence base** Abstract text only; includes variant identification, EMSA result, molecular dynamic simulation outcome, cohort screening counts, and a Fisher's exact test p-value
- **Missing materials affecting confidence** Full methods, variant-level data, cohort ancestry details, EMSA quantification, simulation parameters, burden testing covariates, and any sensitivity analyses

## Reviewer
- **Overall assessment** The abstract presents a potentially important finding linking DMRT1 DM domain variants to male infertility, with a plausible functional mechanism. However, the evidence as presented is insufficient to fully establish causality. The functional assay and simulations are described qualitatively, and the burden testing lacks methodological detail. The POI association is intriguing but based on very few cases and requires replication. The work is relevant to reproductive genetics but needs stronger evidence and clearer reporting.
- **Who would be interested in the results, and why** Clinicians and researchers in reproductive genetics, andrology, and infertility genomics would be interested. The study addresses an unmet need in idiopathic NOA and could inform genetic counseling. The potential POI link broadens relevance to ovarian biology and female infertility.
- **Major strengths** The study targets a clinically significant phenotype with a clear genetic hypothesis. The use of multiple approaches (sequencing, functional assay, simulations, burden testing) is commendable. The inclusion of multiple cohorts and population controls strengthens the genetic association claim. The identification of a specific variant in affected brothers provides a focused starting point.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The functional evidence is not quantified, the burden testing lacks covariate adjustment and population structure control, and the POI claim is based on an insufficient number of cases.
- **Assessment against Nature-style criteria** Originality is moderate; the DMRT1-infertility link is not entirely new, but the specific variant and functional characterization add value. Scientific importance is high given the prevalence of idiopathic NOA. Interdisciplinary readership is plausible, spanning genetics, urology, and reproductive biology. Technical soundness cannot be fully assessed from the abstract; the qualitative descriptions of EMSA and simulations are a concern. Readability for nonspecialists is adequate, though some terms (e.g., DM domain, burden testing) may require context.
- **Recommendation posture** Supportive if technical concerns are resolved, particularly quantification of functional data and robust burden testing. Currently not established from the provided evidence.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Functional evidence
- **Claim pointer** "EMSA assay showed reduced DNA binding of DMRT1P74L and molecular dynamic simulations showed differences in structural and dynamical properties between the wild type protein and DMRT1P74L."
- **Evidence pointer** Abstract, functional assay and simulation sections; location not provided
- **Concern** The abstract states that EMSA showed reduced DNA binding and simulations showed differences, but no quantitative data are provided. There is no mention of effect size, replicates, statistical significance, or comparison to other variants. The simulation differences are not specified in terms of which properties changed or whether they are functionally relevant.
- **Why it matters** Without quantification, the reader cannot assess the magnitude of the functional deficit or whether it is biologically meaningful. A qualitative statement is insufficient to support a causal claim, especially when the variant is heterozygous and the mechanism is proposed to be haploinsufficiency or dominant-negative.
- **Resolution test** Provide EMSA binding curves with quantified dissociation constants or relative binding intensities, including error bars and statistical tests. For simulations, specify which structural or dynamical parameters differed, with confidence intervals or convergence metrics, and relate them to DNA binding function.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Genetic association
- **Claim pointer** "Burden testing showed an excess of rare deleterious DM domain mutations in the infertility cohort compared to gnomAD v.4.0 population-based controls (Fisher’s exact test, p = 1.44 x 10−5)."
- **Evidence pointer** Abstract, burden testing section; location not provided
- **Concern** The burden test uses Fisher's exact test, which does not account for potential confounders such as ancestry, sequencing platform, or variant calling differences between the study cohorts and gnomAD. The abstract does not state how "deleterious" was defined, whether the analysis was restricted to DM domain variants only, or if any sensitivity analyses were performed. The control group is described as "population-based," which may not be phenotypically matched for fertility status.
- **Why it matters** A raw Fisher's exact test is prone to false positives due to population stratification or technical artifacts. The p-value is presented as strong evidence, but without adjustment, the association may not be robust. The definition of "deleterious" is critical; if it is based on in silico predictions, the result may reflect prediction bias rather than true pathogenicity.
- **Resolution test** Perform burden testing with regression models adjusting for ancestry principal components and sequencing batch. Clearly define the variant filtering criteria (e.g., CADD score, allele frequency threshold) and show that results are consistent across different definitions. Include a sensitivity analysis excluding the index family to ensure the signal is not driven by a single pedigree.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** POI association
- **Claim pointer** "Three rare deleterious variants in DMRT1 were found in 104 cases of POI."
- **Evidence pointer** Abstract, POI screening section; location not provided
- **Concern** The abstract reports three variants in 104 POI cases but does not provide a comparison to controls or a statistical test. The claim that this "suggests" a link is speculative without a control frequency or burden analysis. The number of cases is small, and the variants are not described in terms of their location or predicted impact.
- **Why it matters** The POI finding is presented as a novel implication, but without a control comparison, it is impossible to determine whether the variant frequency is elevated. Overinterpretation could mislead clinicians and researchers. The study's primary focus is male infertility, and the POI result should be framed as exploratory.
- **Resolution test** Provide the frequency of rare deleterious DMRT1 variants in a matched control group (e.g., gnomAD females or a local control cohort) and perform a statistical comparison. If the sample size is insufficient, clearly state the limitation and avoid causal language.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Cohort description
- **Affected element** Control group definition
- **Evidence pointer** Abstract, cohort screening section; location not provided
- **Issue** The abstract mentions "639 fertile controls" but does not specify how fertility was confirmed or whether these controls were matched for age and ancestry to the infertility cohort.
- **Required correction** Clarify the fertility criteria for controls and provide basic demographic matching information in the full manuscript.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Variant nomenclature
- **Affected element** Variant description
- **Evidence pointer** Abstract, variant identification section; location not provided
- **Issue** The variant is described as p.Pro74Leu and chr9:g.842059C>T, but the transcript reference (e.g., NM_021951) is not stated. This omission complicates replication and clinical interpretation.
- **Required correction** Include the transcript and genome build (e.g., GRCh38) for the genomic coordinate and the protein reference sequence.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Statistical reporting
- **Affected element** P-value precision
- **Evidence pointer** Abstract, burden testing section; location not provided
- **Issue** The p-value is reported as 1.44 x 10−5, but the abstract does not state whether this is one-tailed or two-tailed, nor whether multiple testing corrections were applied.
- **Required correction** Specify the test direction and any correction for multiple comparisons in the methods.

## Risk / unsupported claims
- The claim that DMRT1 p.Pro74Leu is a "cause" of male infertility is not fully supported by the abstract alone; functional and genetic evidence are suggestive but not definitive.
- The POI link is unsupported as a causal or even associative claim without control comparison or statistical testing.
- The statement that "plausible disease-causing DMRT1 variants were only identified in infertile men" is not verifiable without knowing the full variant filtering criteria and the exact number of controls screened for all variants.
- The distribution of "likely pathogenic variants across the gene" is mentioned but not described, making this claim unassessable from the abstract.